NRF2, Cell Signaling Technology, 20733

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human nuclear factor erythroid 2-related factor 2 (NRF2) and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 17 commercial research antibodies against human nuclear factor erythroid 2-related factor 2 (NRF2) encoded by NFE2L2.

The collection of antibodies was tested using HCT116 WT and NFE2L2 KO MG-132 treated cells in the applications WB (WT and KO cell lysates/30 µg protein), IP (WT cell lysate) and flow cytometry (WT and KO cells) according to YCharOS standard protocols (see reference).

In WB (1:1000 ab dilution) 20733 detected a faint band of appr. 95 kDa in WT cell lysate not observed in KO cell lysate. A band of comparable intensity to the starting material (6%) was observed in the unbound fraction (6%), however the immunoprecipitated fraction was not shown. Flow cytometry using 20733 (1:2000 ab dilution showed overlapping fluorescence intensity distributions for WT and KO cells, with no visible shift between the two populations.